Next Article in Journal
Receptor-Targeted, Magneto-Mechanical Stimulation of Osteogenic Differentiation of Human Bone Marrow-Derived Mesenchymal Stem Cells
Next Article in Special Issue
Combination of Fenretinide and Selenite Inhibits Proliferation and Induces Apoptosis in Ovarian Cancer Cells
Previous Article in Journal
Voltage-Gated Potassium Channel Kv1.3 Is Highly Expressed in Human Osteosarcoma and Promotes Osteosarcoma Growth
Previous Article in Special Issue
ARID1A Mutations and PI3K/AKT Pathway Alterations in Endometriosis and Endometriosis-Associated Ovarian Carcinomas
Review

The Consequence of Oncomorphic TP53 Mutations in Ovarian Cancer

1
Molecular and Cellular Biology Program, University of Iowa, Iowa City, IA 52242, USA
2
Department of Obstetrics and Gynecology, Carver College of Medicine, University of Iowa, Iowa City, IA 52242, USA
3
Holden Comprehensive Cancer Center, Carver College of Medicine, University of Iowa, Iowa City, IA 52242, USA
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2013, 14(9), 19257-19275; https://doi.org/10.3390/ijms140919257
Received: 18 July 2013 / Revised: 13 August 2013 / Accepted: 15 August 2013 / Published: 23 September 2013
(This article belongs to the Special Issue Genes and Pathways in the Pathogenesis of Ovarian Cancer)
Ovarian cancer is the most lethal gynecological malignancy, with an alarmingly poor prognosis attributed to late detection and chemoresistance. Initially, most tumors respond to chemotherapy but eventually relapse due to the development of drug resistance. Currently, there are no biological markers that can be used to predict patient response to chemotherapy. However, it is clear that mutations in the tumor suppressor gene TP53, which occur in 96% of serous ovarian tumors, alter the core molecular pathways involved in drug response. One subtype of TP53 mutations, widely termed gain-of-function (GOF) mutations, surprisingly converts this protein from a tumor suppressor to an oncogene. We term the resulting change an oncomorphism. In this review, we discuss particular TP53 mutations, including known oncomorphic properties of the resulting mutant p53 proteins. For example, several different oncomorphic mutations have been reported, but each mutation acts in a distinct manner and has a different effect on tumor progression and chemoresistance. An understanding of the pathological pathways altered by each mutation is necessary in order to design appropriate drug interventions for patients suffering from this deadly disease. View Full-Text
Keywords: TP53; oncomorphic mutation; ovarian cancer; mutant p53; chemoresistance TP53; oncomorphic mutation; ovarian cancer; mutant p53; chemoresistance
Show Figures

MDPI and ACS Style

Brachova, P.; Thiel, K.W.; Leslie, K.K. The Consequence of Oncomorphic TP53 Mutations in Ovarian Cancer. Int. J. Mol. Sci. 2013, 14, 19257-19275. https://doi.org/10.3390/ijms140919257

AMA Style

Brachova P, Thiel KW, Leslie KK. The Consequence of Oncomorphic TP53 Mutations in Ovarian Cancer. International Journal of Molecular Sciences. 2013; 14(9):19257-19275. https://doi.org/10.3390/ijms140919257

Chicago/Turabian Style

Brachova, Pavla, Kristina W. Thiel, and Kimberly K. Leslie. 2013. "The Consequence of Oncomorphic TP53 Mutations in Ovarian Cancer" International Journal of Molecular Sciences 14, no. 9: 19257-19275. https://doi.org/10.3390/ijms140919257

Find Other Styles

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Back to TopTop